ATE423217T1 - Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten - Google Patents

Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten

Info

Publication number
ATE423217T1
ATE423217T1 AT03711275T AT03711275T ATE423217T1 AT E423217 T1 ATE423217 T1 AT E423217T1 AT 03711275 T AT03711275 T AT 03711275T AT 03711275 T AT03711275 T AT 03711275T AT E423217 T1 ATE423217 T1 AT E423217T1
Authority
AT
Austria
Prior art keywords
levels
treatment
plasminogen activator
cancer patient
assay
Prior art date
Application number
AT03711275T
Other languages
English (en)
Inventor
Walter Carney
Peter Hamer
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE423217T1 publication Critical patent/ATE423217T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03711275T 2002-03-01 2003-02-27 Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten ATE423217T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36121902P 2002-03-01 2002-03-01
US36865802P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
ATE423217T1 true ATE423217T1 (de) 2009-03-15

Family

ID=27791665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711275T ATE423217T1 (de) 2002-03-01 2003-02-27 Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten

Country Status (7)

Country Link
US (4) US20030180819A1 (de)
EP (1) EP1489968B1 (de)
AT (1) ATE423217T1 (de)
AU (1) AU2003213594A1 (de)
DE (1) DE60326214D1 (de)
ES (1) ES2320115T3 (de)
WO (1) WO2003073910A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768324B1 (fr) 1997-09-12 1999-12-10 Jacques Seguin Instrument chirurgical permettant, par voie percutanee, de fixer l'une a l'autre deux zones de tissu mou, normalement mutuellement distantes
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US7666204B2 (en) 1999-04-09 2010-02-23 Evalve, Inc. Multi-catheter steerable guiding system and methods of use
EP1563302B1 (de) * 2002-02-13 2011-09-14 American Diagnostica, Inc. Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
US10667823B2 (en) 2003-05-19 2020-06-02 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
AU2005289474B2 (en) 2004-09-27 2010-12-09 Evalve, Inc. Methods and devices for tissue grasping and assessment
ES2717627T3 (es) 2005-07-29 2019-06-24 Siemens Healthcare Diagnostics Inc Métodos, kits, sistemas y bases de datos relacionados con enfermedades neoplásicas
US20090142330A1 (en) * 2007-10-15 2009-06-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Use of inactive-plasmin to treat chronic inflammatory disease and tumors
US8945177B2 (en) 2011-09-13 2015-02-03 Abbott Cardiovascular Systems Inc. Gripper pusher mechanism for tissue apposition systems
US20140235495A1 (en) 2011-09-23 2014-08-21 Siemens Healthcare Diagnostics Inc. Cell response assay for cancer and methods of producing and using same
US10390943B2 (en) 2014-03-17 2019-08-27 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
US10188392B2 (en) 2014-12-19 2019-01-29 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
CA2981347A1 (en) * 2015-04-02 2016-10-06 Provista Diagnostics, Inc. Biomarkers for detection of ovarian cancer
US10376673B2 (en) 2015-06-19 2019-08-13 Evalve, Inc. Catheter guiding system and methods
US10238494B2 (en) 2015-06-29 2019-03-26 Evalve, Inc. Self-aligning radiopaque ring
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
US10413408B2 (en) 2015-08-06 2019-09-17 Evalve, Inc. Delivery catheter systems, methods, and devices
US10238495B2 (en) 2015-10-09 2019-03-26 Evalve, Inc. Delivery catheter handle and methods of use
US10736632B2 (en) 2016-07-06 2020-08-11 Evalve, Inc. Methods and devices for valve clip excision
US11071564B2 (en) 2016-10-05 2021-07-27 Evalve, Inc. Cardiac valve cutting device
US10363138B2 (en) 2016-11-09 2019-07-30 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10398553B2 (en) 2016-11-11 2019-09-03 Evalve, Inc. Opposing disk device for grasping cardiac valve tissue
US10426616B2 (en) 2016-11-17 2019-10-01 Evalve, Inc. Cardiac implant delivery system
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US10314586B2 (en) 2016-12-13 2019-06-11 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
WO2018209313A1 (en) 2017-05-12 2018-11-15 Evalve, Inc. Long arm valve repair clip
WO2019204741A1 (en) * 2018-04-19 2019-10-24 The Regents Of The University Of California Method and device for detecting siglec12

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12950A (en) * 1855-05-29 Fluid-faucet
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US6271352B1 (en) * 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3672306B2 (ja) * 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO2002099114A2 (en) * 2001-06-01 2002-12-12 Baylor College Of Medicine Methods to determine prognosis after therapy for bladder cancer

Also Published As

Publication number Publication date
EP1489968B1 (de) 2009-02-18
US20080113392A1 (en) 2008-05-15
EP1489968A4 (de) 2006-08-02
WO2003073910A2 (en) 2003-09-12
WO2003073910A3 (en) 2003-10-16
US20120220524A1 (en) 2012-08-30
AU2003213594A1 (en) 2003-09-16
US7732159B2 (en) 2010-06-08
US20090286268A1 (en) 2009-11-19
US20030180819A1 (en) 2003-09-25
EP1489968A2 (de) 2004-12-29
ES2320115T3 (es) 2009-05-19
DE60326214D1 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
ATE438853T1 (de) Diagnostische testvorrichtung
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
DE60228684D1 (de) System zur überwachung der konzentration von analyten in körperflüssigkeiten
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
DE60207979D1 (de) Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE246356T1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
DE60315373D1 (de) Vorrichtung und Verfahren zur Bestimmung der Konzentration von Analyten
NO20074515L (no) Fremgangsmate til prognose for mentale sykdommer, f.eks. autisme og cerebral parese
WO2004069174A3 (en) Monitoring and treatment of amyotrophic lateral sclerosis
ATE441107T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2009043848A3 (en) Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions
ATE529743T1 (de) Verfahren und kits zur tumorigenizitätsdiagnose
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
ATE336003T1 (de) Verfahren zur sepsisdiagnose durch bestimmung von anti-asialo-gangliosid-antikörpern
EP1162457A3 (de) Vielfach-Koagulationstestsystem und Verfahren zu seiner Anwendung
ATE494556T1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
DE60229223D1 (de) Screening-verfahren für den prädiabetiszustand und screening-reagenz
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
ATA19972000A (de) Pibf für die diagnose von tumoren
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties